Skip to main content
An official website of the United States government

Current NCI SBIR Contract Solicitation

Program Solicitation PHS 2025-1

FY25 solicitation release anticipated summer 2024.


The FY25 SBIR Contract Solicitation topic names are now available. See below for the 13 topics that will be included in this year's solicitation.

  • Novel Delivery Systems for RNA-based Cancer Vaccines
  • Development of Cancer Immunoprevention Agents 
  • Synthetic Microbes (Excluding Oncolytic Viruses) for Immuno-Oncology Therapies
  • Development of Novel Therapeutics for HPV-related Precancer
  • Precision Nutrition Interventions to Reduce Cancer-Related Symptoms
  • Drug-Loaded Carrier Particles for Improved Oral Delivery for Colon Cancer Prevention 
  • Antibody-Drug Conjugates as Radiopharmaceutical Theranostics for Cancer 
  • Point of Care Detection of Antibodies Against HPV16/18 E6 and E7 Oncoproteins
  • Point of Care Technologies for GI Cancer Prevention and Early Detection
  • Development of Digital Biomarkers and Endpoints for Clinical Cancer Care 
  • Digital Twin Software for Optimization of Cancer Radiation Therapy
  • Wearable Technologies to Facilitate Remote Monitoring of Cancer Patients Following Treatment 
  • Advanced Biomaterials to Improve Cancer Modeling for Research 

For additional information, please see the NCI Board of Scientific Advisors (BSA) presentation on the FY25 SBIR Contract Solicitation topics.

Applicants must use the Contract Proposal Submission (eCPS) website to submit their proposal. No other method of proposal submission is permitted. Instructions for electronic submission are provided in the solicitation. Actual contract topic numbers will be available in the solicitation.

For more information, contact Cherie Wells, contract analyst in the Office of Acquisitions, at


For reference, see below for the 11 topics that were included in last year's FY24 SBIR Contract solicitation.


  • Updated:

If you would like to reproduce some or all of this content, see Reuse of NCI Information for guidance about copyright and permissions. In the case of permitted digital reproduction, please credit the National Cancer Institute as the source and link to the original NCI product using the original product's title; e.g., “Current NCI SBIR Contract Solicitation was originally published by the National Cancer Institute.”